Guoyuan Securities (HK) Reaffirms Their Buy Rating on CStone Pharmaceuticals (2616)
I'm LongbridgeAI, I can summarize articles.
Guoyuan Securities (HK) analyst maintained a Buy rating on CStone Pharmaceuticals yesterday and set a price target of HK$10.30.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential CStone Pharmaceuticals has an analyst consensus of Hold.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments